Lantern Pharma (LTRN) News Today $3.68 +0.14 (+3.95%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage TrialMay 5 at 9:52 AM | uk.finance.yahoo.comLantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)May 5 at 8:55 AM | businesswire.comLantern Pharma (LTRN) to Release Quarterly Earnings on ThursdayMay 1, 2025 | americanbankingnews.comLantern Pharma initiated with a Buy at Lake StreetApril 3, 2025 | markets.businessinsider.comLake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy RecommendationApril 3, 2025 | msn.comEarnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expensesMarch 29, 2025 | uk.investing.comLTRN: 2024 Financial ResultsMarch 28, 2025 | finance.yahoo.comLantern Pharma outlines 2025 clinical milestones and key updates on oncology trialsMarch 27, 2025 | msn.comLantern Pharma Inc. (LTRN) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comLantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial ResultsMarch 27, 2025 | businesswire.comPreview: Lantern Pharma's EarningsMarch 27, 2025 | benzinga.comLTRN: M&A Illuminates GBM ValueMarch 10, 2025 | finance.yahoo.comLantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction TechFebruary 20, 2025 | insidermonkey.comLantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction TechFebruary 20, 2025 | msn.comLantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer TherapiesJanuary 27, 2025 | insidermonkey.comLantern Pharma Inc. (LTRN): AI-Driven Cancer Drug DevelopmentJanuary 17, 2025 | insidermonkey.comIs Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?December 22, 2024 | finance.yahoo.comAI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in TaiwanDecember 10, 2024 | insidermonkey.comLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONICâ„¢ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsDecember 9, 2024 | businesswire.comLantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast CancerDecember 7, 2024 | insidermonkey.comLantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast CancerDecember 7, 2024 | msn.comLantern Pharma Shares Rise After Fast-Track Designation for Cancer TreatmentDecember 4, 2024 | marketwatch.comLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)December 4, 2024 | businesswire.comLantern Pharma doses first patient in LP-300 trial expansion cohortNovember 20, 2024 | markets.businessinsider.comLTRN: Pediatric Rare Cancer in FocusNovember 12, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comLantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...November 9, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comLantern Pharma Advances AI-Driven Cancer TherapiesNovember 8, 2024 | markets.businessinsider.comLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 7, 2024 | businesswire.comStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNovember 5, 2024 | finance.yahoo.comLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETOctober 31, 2024 | businesswire.comLantern Pharma to Host & Participate in Two Public Webinars During OctoberOctober 21, 2024 | finance.yahoo.comLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDAOctober 15, 2024 | finance.yahoo.comLantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...October 9, 2024 | finance.yahoo.comLantern Pharma (NASDAQ:LTRN) Stock, Insider Trading ActivityOctober 9, 2024 | benzinga.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersSeptember 24, 2024 | finance.yahoo.comLantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184September 23, 2024 | marketwatch.comLantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And HepatoblastomaSeptember 23, 2024 | markets.businessinsider.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's CancersSeptember 23, 2024 | tmcnet.comLantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a MillionaireAugust 31, 2024 | msn.comLTRN: Second Quarter ResultsAugust 12, 2024 | msn.comLantern Pharma Inc. (LTRN) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.comLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesAugust 9, 2024 | tmcnet.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024August 8, 2024 | investorplace.comLTRN: Harmonic Clinical UpdateAugust 6, 2024 | msn.comLTRN Aug 2024 2.000 putAugust 5, 2024 | ca.finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Sees Significant Decline in Short InterestLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large drop in short interest in June. As of June 15th, there was short interest totalling 333,500 shares, a drop of 20.6% from the May 31st total of 419,800 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 163,200 shares, the short-interest ratio is presently 2.0 days.June 29, 2024 | marketbeat.comLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284June 12, 2024 | businesswire.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 10,000 SharesMay 29, 2024 | insidertrades.com Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼0.000.72▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼31▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PBYI News CYBN News ACRS News EPRX News ADCT News FATE News NKTX News OGI News GLSI News FTLF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LTRN Stock Free LTRN Stock Alerts